Valneva (VALN) Expected to Announce Earnings on Wednesday

Valneva (NASDAQ:VALN - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $55.64 million for the quarter.

Valneva Stock Up 2.3 %

Shares of VALN opened at $7.06 on Wednesday. The company has a market capitalization of $573.70 million, a P/E ratio of -54.31 and a beta of 1.93. Valneva has a one year low of $3.62 and a one year high of $9.50. The business's 50 day simple moving average is $5.97 and its 200-day simple moving average is $5.61. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research note on Friday, February 28th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.